Trestolone 100
💉
Trestolone 100 Dragon Pharma
Trestolone Enanthate (MENT) 100 mg/ml · 19-Nor · Aromatizes · Advanced
🧬
Class
19-Nor / MENT
7α-methyl-19-nortestosterone
⏱️
Ester / Half-Life
Enanthate · ~7–10 days
2× per week · stable plasma
⚠️
Aromatization
Yes — to 7α-methyl-E2
AI required · symptom-guided
🎯
User Level
Advanced
potent suppressor · AI + Caber
Typical Dose
100–200 mg/week
0.5–1 ml × 2/week
Injection Frequency
2× per week
Mon + Thu or similar
Cycle Length
10–14 weeks
enanthate protocol
Lab Tested
Out of Stock
Trestolone 100 Dragon Pharma — Overview
Trestolone 100 Dragon Pharma is Trestolone Enanthate (MENT) at 100 mg/ml — a 7α-methyl-19-nortestosterone with an androgen receptor affinity estimated at ~10× testosterone and a pharmacological profile that separates it from every other AAS in the Dragon Pharma lineup. Unlike trenbolone, MENT aromatises — to 7α-methyl-estradiol, an estrogen more potent than standard E2 — which means it can provide the estrogenic support joints, libido, and mood require without a mandatory exogenous testosterone base. Unlike nandrolone, it does not convert via 5-alpha reductase, eliminating the DHT-pathway androgenic effects on scalp and prostate. The critical management challenge: standard E2 immunoassay tests do not detect 7α-methyl-E2, so aromatisation control is symptom-guided rather than lab-number-guided. Available at Steroid Warehouse as part of the Dragon Pharma advanced injectable range.
Trestolone Enanthate · MENT · 100 mg/ml 19-Nor · Aromatizes · No 5AR Conversion Lean Bulk Recomp Advanced
On this page
About the Compound: Trestolone Enanthate (MENT)
- 7α-methyl-19-nortestosterone — a structurally distinct 19-Nor AAS — the 7α-methyl group blocks 5-alpha reductase conversion, eliminating DHT-pathway androgenic effects on hair follicles and prostate; MENT does not bind SHBG, meaning essentially 100% of circulating compound is free and biologically active; AR affinity is estimated at ~10× testosterone, making it effective at doses of 100–200 mg/week where comparable testosterone protocols run 500–600 mg/week
- Aromatizes — but the product is not detectable on standard E2 assays — MENT converts to 7α-methyl-estradiol (7α-ME2), which is more potent than standard E2 and binds estrogen receptors effectively; standard immunoassay E2 tests calibrated for regular estradiol do not detect 7α-ME2; AI use must be guided by symptoms (water retention, nipple sensitivity, mood, libido) and dose adjustments made accordingly, not by a lab number
- 19-Nor progestogenic activity — same mechanism as nandrolone and trenbolone; binds progesterone receptors and stimulates prolactin release; Caberlin is required from day one; unlike trenbolone, MENT's estrogenic activity partially offsets some progestogenic prolactin effects, but prolactin monitoring remains mandatory
- Can be run without a mandatory exogenous testosterone base — because MENT aromatises to an active estrogen, it provides joint lubrication, libido support, and mood stability that trenbolone-only protocols cannot; a low-dose testosterone base (Enantat 250 Dragon Pharma at 200 mg/week) is still common for additional androgen pathway support, but is not pharmacologically mandatory as it is with trenbolone
Active Substance
Trestolone Enanthate (MENT)
Concentration
100 mg/ml
Ester / Half-Life
Enanthate · ~7–10 days
Aromatization
Yes — to 7α-methyl-E2
5AR Conversion
None — no DHT pathway
User Level
Advanced
What Trestolone 100 Does
- High-potency lean mass accrual per mg of compound — AR affinity ~10× testosterone means 150 mg/week of MENT delivers androgenic stimulus comparable to substantially higher testosterone doses; lean mass gained is high quality with controlled estrogenic load; the combination of anabolic potency and aromatisation to an active estrogen produces lean, full muscle tissue rather than the dry, deflated appearance of non-aromatising compounds
- Simultaneous anabolic and estrogenic physiological support — MENT covers both the AR-mediated anabolic effect and the ERα-mediated estrogenic support (joint health, libido, mood, cardiovascular lipid management) from a single compound; this is pharmacologically unusual among AAS and the key reason solo MENT protocols are viable in a way that solo trenbolone is not
- Body recomposition — high AR affinity drives lean mass accrual and nutrient partitioning improvement; 7α-ME2 provides estrogenic substrate for joint and libido maintenance during caloric deficit; combination produces favourable recomposition outcomes in experienced athletes
- No 5AR-pathway androgenic side effects — because MENT does not convert to DHT or DHT-like metabolites, androgenic effects in scalp, prostate, and skin driven by the DHT pathway are absent; users who experience significant androgenic alopecia or acne on testosterone will see less of both on MENT at equivalent anabolic dose
- Strong HPG axis suppression — MENT was originally developed as a male contraceptive because of its potent LH and FSH suppression; this suppression is more complete and rapid than testosterone at equivalent doses and requires a structured PCT approach
Who It's For
- Key differentiator vs testosterone and nandrolone — MENT is not a first AAS compound; its defining advantages are the combination of high anabolic potency per mg, the absence of the DHT pathway, and self-sufficient estrogenic coverage without a mandatory test base; these advantages are relevant only to athletes experienced enough to manage symptom-guided AI dosing without standard E2 lab reference points, and to run a robust PCT after a strongly suppressive compound
- Best scenario — experienced AAS users seeking high anabolic output with reduced DHT-pathway androgenic side effects (scalp, prostate); athletes who tolerate estrogen well and want the estrogenic support MENT provides without stacking separate compounds; users building lean mass or recomping at relatively low injection volumes compared to testosterone-based protocols at equivalent anabolic intensity
- Choose something else instead — users who require reliable E2 lab monitoring to manage aromatisation safely should use Enantat 250 Dragon Pharma where standard E2 assays apply directly; users seeking a 19-Nor compound with a well-established multi-decade clinical and anecdotal track record should use Deca 300 Dragon Pharma (nandrolone decanoate) instead; users who want to avoid any aromatisation entirely should use trenbolone
Trestolone 100 vs Alternatives
| Compound | Key Differences | Choose Trestolone 100 When | Choose Alternative When |
|---|---|---|---|
| Enantat 250 Dragon Pharma Testosterone Enanthate 250 mg/ml |
Standard testosterone; aromatises to regular E2 (measurable by any lab assay); well-established safety profile; requires 400–600 mg/week for comparable anabolic output to MENT at 150–200 mg/week; converts to DHT via 5AR; universal base compound for stacking | High anabolic output with reduced injection volume is the goal, AND the user is experienced with symptom-guided AI management | Reliable E2 lab monitoring is needed, the user prefers a well-studied base compound, or MENT's more complex management is not appropriate for the current experience level |
| Deca 300 Dragon Pharma Nandrolone Decanoate 300 mg/ml |
19-Nor with decades of anecdotal and clinical data; aromatises minimally; joint-supporting progestogenic activity; requires testosterone base (does not self-cover estrogenic needs); AR affinity ~2.4× testosterone vs MENT's ~10×; well-understood prolactin risk management | Higher anabolic potency per mg is needed, DHT pathway avoidance is a priority, and the user accepts symptom-guided AI management in exchange for MENT's more concentrated anabolic output | Established 19-Nor track record and straightforward cycle management with measurable lab markers are more important than MENT's concentration advantage |
| NPP 150 Dragon Pharma Nandrolone Phenylpropionate 150 mg/ml |
Shorter ester (3–5 day half-life) version of nandrolone; EOD injections; faster clearance for unknown individual response; milder overall anabolic output; same prolactin risk; requires testosterone base | MENT's potency and self-sufficient estrogenic coverage are the specific requirements at the current cycle stage | The user is exploring 19-Nor compounds for the first time and needs a milder, short-ester format where sides resolve quickly if tolerance is poor |
Combinations
| Goal | Stack | Notes |
|---|---|---|
| Solo MENT protocol (no external test base) | Trestolone 100 150 mg/week (0.75 ml × 2) + Arimidex Dragon Pharma 0.5 mg EOD (symptom-guided) + Caberlin 0.25 mg 2×/week | MENT's aromatisation to 7α-ME2 provides estrogenic support without exogenous testosterone; AI dose adjusted by symptoms (libido, water, nipple sensitivity), not by standard E2 lab values which will not detect 7α-ME2; Caberlin controls prolactin from 19-Nor activity from day one |
| MENT + low-dose Test E base | Trestolone 100 150 mg/week + Enantat 250 Dragon Pharma 200 mg/week + Arimidex 0.5 mg EOD + Caberlin 0.25 mg 2×/week | Test E at 200 mg/week provides measurable standard E2 as a baseline lab reference; MENT provides the primary anabolic load; the combination covers both measurable E2 from testosterone aromatisation and unmeasured 7α-ME2 from MENT; monitor symptoms for total estrogenic load rather than E2 number alone |
| Lean bulk (higher anabolic output) | Trestolone 100 200 mg/week (1 ml × 2) + Enantat 250 400 mg/week + Aromasin Dragon Pharma 12.5 mg EOD + Caberlin 0.25 mg 2×/week | Aromasin preferred over Arimidex at higher combined aromatising load; total estrogenic burden from both Test E and MENT aromatisation is significant; symptom check at week 3–4 alongside available lipid and prolactin labs |
| Lean / dry recomp | Trestolone 100 150 mg/week + Enantat 250 200 mg/week + Masteron 200 Dragon Pharma 400 mg/week + Caberlin 0.25 mg 2×/week | Masteron 200 (drostanolone enanthate) provides matched-ester anti-estrogenic DHT-derivative overlay; partially controls MENT's estrogenic load without a dedicated AI; adds muscle hardness and density; monitor for E2 deficiency symptoms (joint pain, libido drop, mood) as Masteron may over-suppress if combined with an AI simultaneously |
| Lean mass + oral add-on | Trestolone 100 150 mg/week + Enantat 250 200 mg/week + Anavar 50 Dragon Pharma 40–60 mg/day (weeks 5–14) + Arimidex 0.5 mg EOD (symptom-guided) + Caberlin 0.25 mg 2×/week | Anavar adds SHBG suppression, lean mass, and strength with no aromatisation; complements MENT's anabolic profile without increasing estrogenic load; monitor ALT/AST monthly with oral use; start Anavar from week 5 once MENT steady-state plasma is established |
Side Effects & Management
| What May Occur | Background | How to Handle It |
|---|---|---|
| Estrogenic effects (water retention, gynecomastia) | MENT aromatises to 7α-methyl-E2; standard E2 immunoassay labs will read low or normal because the assay does not detect this metabolite; estrogenic side effects can develop despite a lab-normal E2 reading — symptom assessment is the primary guide | Arimidex Dragon Pharma 0.5 mg EOD or Aromasin Dragon Pharma 12.5 mg EOD; titrate by symptoms (water, nipple sensitivity, mood) not by standard E2 lab number; do not over-suppress — MENT's estrogenic activity is needed for joint and libido support if not running a test base |
| Prolactin elevation | 19-Nor progestogenic activity stimulates prolactin; MENT's estrogenic component partially modulates this but does not eliminate the 19-Nor prolactin risk | Caberlin (Cabergoline) 0.25 mg 2×/week from day one; confirm prolactin at week 4; increase to 0.5 mg 2×/week if >30 ng/mL; target <25 ng/mL throughout cycle |
| Strong HPG suppression | MENT was developed as a male contraceptive specifically because of its rapid and near-complete LH and FSH suppression; more profound than equivalent testosterone doses; endogenous testosterone production ceases quickly and recovery requires a structured PCT approach | Do not skip HCG bridge; run full 6-week SERM protocol post-cycle; confirm LH/FSH recovery at PCT week 4; extended suppression past PCT week 6 with low LH/FSH warrants specialist evaluation |
| Blood pressure and hematocrit elevation | Erythropoiesis stimulation and androgenic vasoconstriction; similar in mechanism to other AAS but intensity at equivalent anabolic dose may differ from testosterone due to MENT's different receptor binding profile | Weekly BP monitoring; target <130/85 mmHg; Amlip (Amlodipine) 5 mg/day if persistent >140/90; hematocrit >50%: Ecosprin (Aspirin) 75 mg/day + hydration; >54%: therapeutic phlebotomy |
| Lipid suppression | AAS-mediated HDL reduction and LDL elevation; MENT's estrogenic component (7α-ME2) may offer some HDL-protective effect compared to non-aromatising AAS, but net lipid impact is still meaningful at anabolically effective doses | Lipid panel at baseline and week 8; HDL <35 or LDL >160: Atorvastatin 40 mg Dragon Pharma or Rosulip (Rosuvastatin) 10 mg/day; omega-3 3–4 g/day throughout |
| Androgenic effects (acne, hair loss) | MENT does not convert via 5-alpha reductase, eliminating the DHT-pathway contribution to androgenic alopecia and prostate effects; direct AR activity in skin and hair follicles is still present from MENT itself; androgenic side effects are generally milder than testosterone at equivalent anabolic dose | Acne (if present): Accutane Dragon Pharma 10–20 mg/day; finasteride is not indicated — MENT does not use the 5AR pathway so Finasteride Dragon Pharma provides no benefit for MENT-specific androgenic effects |
Bloodwork Monitoring
| Lab | When to Test | Target & Action Threshold |
|---|---|---|
| Hematocrit & Hemoglobin | Baseline; week 6; end of cycle | Hematocrit <50% · Hemoglobin <17.5 g/dL — >52%: Ecosprin 75 mg/day + hydration; >54%: phlebotomy or dose reduction |
| Lipid Panel | Baseline; week 8 | HDL >40 mg/dL · LDL <130 mg/dL — if HDL <35 or LDL >160: initiate statin; re-test 4 weeks later |
| Estradiol (E2) | Week 3; week 8 | Standard immunoassay will NOT detect 7α-methyl-E2 from MENT — use result as a partial indicator of Test E aromatisation only (if Test E is in the stack); manage total estrogenic load by symptoms, not lab number alone |
| Prolactin | Week 4; week 8 | Target <25 ng/mL — 25–35: maintain Caberlin 0.25 mg 2×/week; >35: increase to 0.5 mg 2×/week |
| Blood Pressure | Weekly (home cuff) | Target <130/85 mmHg — persistent >140/90: Amlip 5 mg/day; if uncontrolled: add Sartel (Telmisartan) 40–80 mg/day |
| LH & FSH | End of PCT only | Both recovering toward mid-normal — MENT's strong suppression means slower LH/FSH recovery is common; persistently suppressed at PCT week 4: extend SERM to week 8 |
| Total Testosterone | 4–6 weeks post-PCT | >400 ng/dL confirms HPG recovery — <300 ng/dL at 6 weeks post-PCT with flat LH/FSH: specialist assessment given MENT's stronger suppressive profile |
Post-Cycle Recovery
Trestolone Enanthate's 7–10 day half-life requires the same 2-week clearance window as Testosterone Enanthate. MENT's more profound HPG suppression compared to testosterone makes the HCG bridge mandatory rather than optional.
| Compound | Protocol | Notes |
|---|---|---|
| HCG 5000 IU Dragon Pharma | 500 IU EOD × 14–21 days; start 3–5 days after last injection | MENT suppresses LH/FSH more completely than testosterone; an extended HCG bridge (up to 3 weeks) is appropriate before SERM start; discontinue before SERM to avoid intratesticular E2 interference |
| Nolvadex Dragon Pharma | 40 mg/day weeks 1–2; 20 mg/day weeks 3–6. Start 14 days after last injection | Primary SERM; 6-week protocol minimum for MENT cycles; confirm LH/FSH at week 4 of PCT; if recovery is slow, extend to week 8 at 20 mg/day |
| Clomid Dragon Pharma | 50/50/25/25 mg/day × 4 weeks alongside Nolvadex (standard for all MENT cycles) | Given MENT's strong HPG suppression, dual SERM is recommended as the default rather than an add-on; Clomid's stronger LH-stimulating potency complements Nolvadex's ER-blocking action |
| Enclomiphene Dragon Pharma | 25 mg/day × 6 weeks as alternative to Clomid | Preferred over full clomiphene for users who experience mood or visual side effects from Clomid; equal LH-stimulating potency without the zuclomiphene estrogenic antagonist component |
For full PCT timing and dosing context, see the PCT guide.
Practical Summary
- Standard E2 labs will not tell you what you need to know — MENT's aromatisation product (7α-methyl-E2) is invisible to standard immunoassay E2 tests; manage AI dose by symptoms: if water retention, nipple sensitivity, and mood are controlled without joint pain or libido loss, the estrogenic balance is right; bloodwork confirms prolactin, hematocrit, and lipids — not total estrogenic load from MENT
- Caberlin from day one — MENT is a 19-Nor compound; prolactin elevation follows the same timeline as nandrolone and trenbolone; 0.25 mg twice weekly is the prophylactic starting dose; confirm prolactin at week 4 and adjust
- Do not skip the HCG bridge — MENT suppresses LH and FSH more completely and rapidly than testosterone; recovery without HCG priming is slower; 500 IU EOD for 14–21 days before SERM start is the minimum bridge for a MENT cycle
- Finasteride is not useful here — MENT does not use the 5-alpha reductase pathway; androgenic effects on scalp and skin from MENT are mediated directly through the androgen receptor, not via DHT; finasteride blocks DHT from testosterone in a stack but has no effect on MENT's direct androgenic activity
- Dual SERM is the default for PCT, not an upgrade — MENT's suppressive depth makes Nolvadex + Clomid (or Enclomiphene) the standard PCT approach; a Nolvadex-only protocol should be reserved for shorter or lower-dose cycles and confirmed by LH/FSH recovery tracking
- 100–200 mg/week achieves what 500–600 mg/week testosterone does anabolically — the concentration advantage is real but requires disciplined symptom monitoring in exchange; users who want anabolic output with standard measurable E2 and simpler management should use testosterone or nandrolone instead
Trestolone 100 Dragon Pharma occupies a specific position in advanced AAS pharmacology: high anabolic output per mg, no DHT-pathway androgenic effects, and self-sufficient estrogenic coverage — in exchange for a management protocol that relies on symptom assessment over lab numbers. For experienced athletes who understand MENT's unique pharmacological profile and are prepared to manage it correctly, steroidwarehouse.com's Dragon Pharma Trestolone 100 delivers consistent, pharmaceutical-grade MENT Enanthate at the concentration and purity that advanced protocols require.
References
| Source | Topic | Link |
|---|---|---|
| New England Journal of Medicine / PubMed | Bhasin et al. 1996 — randomized controlled trial using 600 mg/week testosterone enanthate for 10 weeks, showing increased fat-free mass, muscle size, and strength, especially when combined with resistance training; foundational evidence for supraphysiologic androgen anabolic effects | Bhasin S, et al. (1996) ↗ |
| NCBI Bookshelf / StatPearls | Anabolic steroids overview — synthetic testosterone-derived AAS pharmacology, androgen receptor mechanism, anabolic-androgenic effects, oral and injectable steroid classes, misuse patterns, monitoring, and adverse effect profile | StatPearls: Anabolic Steroids ↗ |
| NCBI Bookshelf / Endotext | Androgen physiology and pharmacology — testosterone and androgen derivative mechanisms of action, androgen receptor activity, HPG axis suppression, 5α-reduction, estradiol aromatization, synthetic androgen pharmacology, and androgen misuse context | Endotext: Androgen Physiology, Pharmacology, Use and Misuse ↗ |
| International Journal of Andrology / PubMed | Sundaram & Kumar 2000 — review of 7α-methyl-19-nortestosterone (MENT) as a candidate androgen for male contraception and androgen replacement therapy; covers MENT's high androgenic potency, resistance to 5α-reduction, aromatization potential, and rationale for reduced prostate stimulation compared with testosterone | Sundaram K & Kumar N (2000) ↗ |
| Circulation / PubMed | Baggish et al. 2017 — human study linking long-term illicit anabolic-androgenic steroid use with myocardial dysfunction and accelerated coronary atherosclerosis; useful context for cardiovascular risk discussion around long-term AAS exposure | Baggish AL, et al. (2017) ↗ |
What is Trestolone 100?
Trestolone 100 is an injectable anabolic steroid (Trestolone Enanthate) for muscle growth; see What is Trestolone 100. It's extremely potent—consult professionals for safe use.
How much Trestolone 100 for bodybuilding?
200-400 mg/week, split into 2-3 injections; see How Much Trestolone 100 for Bodybuilding. Start at 200 mg—consult professionals for dosing.
How does Trestolone 100 work?
It binds androgen receptors for massive muscle growth; see Mechanism of Action. It delivers rapid results—monitor with labs.
What is Trestolone 100 used for?
It's used for muscle growth, strength, and fat loss in bulking or cutting; see Key Benefits. It suits advanced users—use with professional oversight.
How long does it take to notice effects from Trestolone 100?
Due to its fast-acting nature, users often report noticeable changes in strength, muscle fullness, and performance within a relatively short period of consistent use.
What are the main benefits of Trestolone 100?
Commonly reported benefits include rapid muscle mass gains, significant strength increases, improved muscle density, enhanced recovery, and strong anabolic activity.
Is Trestolone 100 used for bulking or cutting?
Trestolone 100 is most commonly associated with aggressive bulking and recomposition phases due to its strong anabolic effects and rapid results.
What are the possible side effects of Trestolone 100?
Potential side effects may include estrogen-related effects, acne, oily skin, mood changes, and strong suppression of natural testosterone production.
Related Products
Available Domestic
Lab Tested
Masteron 100 Dragon Pharma
Drostanolone Propionate 100 mg/ml · DHT-derived injectable · non-aromatizing
Class
DHT-Derived
Injectable AAS
Ester / Active Life
Propionate
~2–3 days
Aromatization
None
No estrogen conversion
User Level
Intermediate
to Advanced
Typical Dose
300–500 mg
per week
Injection Frequency
EOD
every other day
Cycle Length
8–12 weeks
typical range
Available Domestic
Lab Tested
Anadrol Inj Dragon Pharma
Oxymetholone 50 mg/ml · DHT-derived injectable · non-aromatizing via aromatase
Class
DHT-Derived
Injectable AAS
Ester / Active Life
No ester
~8–16 hours
Aromatization
None
No estrogen via aromatase
User Level
Intermediate
to Advanced
Typical Dose
50–100 mg
per day
Injection Frequency
Daily
short active life
Cycle Length
4–6 weeks
typical range
Lab Tested
Cut Long 300 Dragon Pharma
Test E 100 · Tren E 100 · Masteron E 100 · 300 mg/ml
Category
Injectable AAS Blend
3-compound / long esters
Composition
300 mg/ml total
Test E · Tren E · Drost E
Context
Cutting · Recomp
lean mass · fat loss · density
Administration
IM injection
once or twice weekly
Typical Dose
300–600 mg
per week
Frequency
1–2× / week
long ester schedule
Cycle Length
10–16 weeks
PCT ~2 wks after last inj
Available Domestic
Lab Tested
Cut Mix 150 Dragon Pharma
Test P 50 · Tren A 50 · Masteron P 50 · 150 mg/ml
Category
Injectable AAS Blend
3-compound / short esters
Composition
150 mg/ml total
Test P · Tren A · Drost P
Context
Cutting · Recomp
lean mass · fat loss · density
Administration
IM injection
every other day (EOD)
Typical Dose
1–1.5 ml EOD
~525–787 mg/week
Frequency
EOD
short ester schedule
Cycle Length
8–10 weeks
PCT 3–4 days after last inj
Available Domestic
Best Seller
Lab Tested
Cypionat 250 Dragon Pharma
Testosterone Cypionate · 250 mg/ml · Long-ester injectable
Class
Anabolic Steroid
injectable testosterone ester
Half-life
~8 days
twice-weekly injection
Context
Bulking · TRT
mass, strength, hormone base
Administration
IM injection
glute, quad, or delt
Typical Dose
250–500 mg/wk
1–2 ml per week
Frequency
2× per week
Mon / Thu split
Cycle Length
12–16 weeks
PCT required after
Lab Tested
Deca 200 / NPP 150 Dragon Pharma
Nandrolone Decanoate 200 mg + Phenylpropionate 150 mg · 350 mg/ml
Class
Anabolic Steroid
dual nandrolone ester blend
Half-life
Deca ~15d · NPP ~5d
dual-phase release
Context
Bulking · Joints
mass, recovery, collagen
Administration
IM injection
weekly or E5D
Typical Dose
300–500 mg/wk
always with testosterone base
Frequency
Weekly / E5D
stable dual-ester levels
Cycle Length
12–16 weeks
PCT 3 weeks after last pin
Lab Tested
Deca 200 / Test E 200 Dragon Pharma
Nandrolone Decanoate 200 mg + Testosterone Enanthate 200 mg · 400 mg/ml
Class
Anabolic Steroid
classic test + deca blend
Half-life
Test E ~8d · Deca ~15d
long-acting, weekly dosing
Context
Bulking · Joints
mass, strength, recovery
Administration
IM injection
weekly or E5D
Typical Dose
400–800 mg/wk
of the blend (200–400 mg each)
Frequency
Weekly / E5D
both esters covered
Cycle Length
12–16 weeks
PCT 3 weeks after last pin
Available Domestic
Best Seller
Lab Tested
Deca-300 Dragon Pharma
Nandrolone Decanoate · 300 mg/ml
Class
Anabolic Steroid
19-nor testosterone derivative
Half-life
~15 days
decanoate ester, weekly dosing
Context
Bulking · Joints
mass, collagen, recovery
Administration
IM injection
weekly or E5D
Typical Dose
300–600 mg/wk
always with testosterone base
Frequency
Weekly / E5D
stable long-ester levels
Cycle Length
12–16 weeks
PCT 3 weeks after last pin